Food and Behaviour Research

Donate Log In

Alcohol: What Women Need to Know - BOOK HERE

13 December 2016 - NutraIngredients - Omega-3s may turn off chronic low-grade inflammation in obese women: Study

Stephen Daniells

Adding omega-3 supplements to a calorie-controlled diet may combat the chronic inflammation associated with obesity by boosting specialized pro-resolving mediators derived from DHA, says a new study European scientists.

FAB RESEARCH COMMENT:

Obesity is linked to chronic, low-grade inflammation - which is thought to contribute to many of its negative health consequences.

In this placebo-controlled trial, signifcant reductions in a range of measures of inflammation in obese women were reduced following 3 months of dietary supplementation with long-chain Omega-3 fatty acids (EPA and DHA).

The reductions in inflammatory biomarkers were also shown to relate to the production of both 'resolvins' and 'protectins' - substances made within the body from omega-3 DHA that actively help to resolve inflammation.

These findings strongly support exsiting evidence that an increased dietary intake of the long-chain omega-3 EPA and DHA (found naturally in fish and seafood, and also in some special forms of algae) can help to reduce inflammation, and may therefore be of benefit in alleviating the many health problems associated with obesity in which inflammation plays a role.

Read the related research here:

Adding omega-3 supplements to a calorie-controlled diet may combat the chronic inflammation associated with obesity by boosting specialized pro-resolving mediators derived from DHA, says a new study European scientists.

Three months of DHA + EPA supplementation resulted in significant reductions in markers of inflammation such as cytokines, adhesion molecules and acute phase proteins, and an increase in specialized pro-resolving mediators (SPMs) in 59 obese women, according to results published in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids .

“Of great interest is the observation that DHA-derived resolvins and protectins were increased in plasma of women with obesity given [omega-3] supplements. These DHA-derived mediators have a key role in resolution of inflammation suggesting that in obesity [omega-3] may not only reduce inflammation but may actively resolve it,” wrote researchers from Poland and the UK.

“Teaching us the value of being able to modulate the inflammatory response”

Commenting independently on the study’s findings, Dr Gerard Bannenberg, director of compliance & scientific outreach for the Global Organization for EPA and DHA Omega-3s (GOED), told us:

“This study by Polus et al. provides further supports to the description of obesity as a disorder that is characterized by inflammation that is measurable at systemic level. Interestingly, the inflamed state was shown to be decreased when improving the participant’s omega-3 status by supplemental EPA and DHA intake.

“Measurable increases in pro-resolving lipid mediators derived from DHA, following three months of increased omega-3 intake, indicate that a pro-resolving response is activated that the authors believe may be helping to limit and turn off the chronic low-grade inflammation in the obese female participants.

“Through a comprehensive documentation of several aspects of inflammation in obesity, this study shows that several molecular events previously elucidated in animal studies are also operative in humans, and can likewise be modulated by improving one’s omega-3 status.

“Future human research employing well-controlled dietary intervention studies that take into account the tissue status of omega-3 polyunsaturated fatty acids in the body will further teach us the value of being able to modulate the inflammatory response in a range of diseases that are characterized by inflammation.”

Study details

The researchers, led by Anna Polus from Jagiellonian University, Krakow, randomly assigned 59 moderately obese women with an average age of 46.6 to receive either omega-3 supplements containing 1,290 mg per day of DHA and 270-450 mg per day of EPA (EPAX 1050 TG; EPAX AS) or placebo for three months.

Results showed that the calorie-controlled diet produced significant reductions in body weight, fat mass, and BMI in both groups, but only the omega-3 supplemented group displayed significant increases in EPA and DHA.

In addition, only the omega-3 group had significantly decreased concentrations of several inflammatory markers, including E-selectin (SELE), monocyte chemoattractant protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1), platelet/endothelial cell adhesion molecule 1 (PECAM-1), and C-reactive protein (CRP). The omega-3 group also experienced significant reduction to fasting triglycerides and insulin levels.

The researchers also found that there was an increase in SPMs correlated with up-regulated gene expression of enzyme ALOX5, which plays a role in SPM production.

Effects on specific genetic pathways linked to catabolism of fatty acids in mitochondria, the synthesis of phospholipids, mitochondrial electron transport chain, and antioxidant enzymes were also reported.

“We conclude that [omega-3 polyunsaturated fatty acids] can combat low grade inflammation in obesity through an increase of DHA-derived pro-resolving mediators and a decrease in a range of pro-inflammatory proteins.”